174 related articles for article (PubMed ID: 30107597)
1. Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
Tejada Neyra MA; Neuberger U; Reinhardt A; Brugnara G; Bonekamp D; Sill M; Wick A; Jones DTW; Radbruch A; Unterberg A; Debus J; Heiland S; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Bendszus M; Kickingereder P
Neuro Oncol; 2018 Oct; 20(11):1517-1524. PubMed ID: 30107597
[TBL] [Abstract][Full Text] [Related]
2. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
3. Age-associated brain regions in gliomas: a volumetric analysis.
Wang Y; Liu S; Fan X; Li S; Wang R; Wang L; Ma J; Jiang T; Ma W
J Neurooncol; 2015 Jun; 123(2):299-306. PubMed ID: 25981802
[TBL] [Abstract][Full Text] [Related]
4. Mapping genetic factors in high-grade glioma patients.
Yuan Y; Yunhe M; Xiang W; Yanhui L; Ruofei L; Jiewen L; Qing M
Clin Neurol Neurosurg; 2016 Nov; 150():159-163. PubMed ID: 27668860
[TBL] [Abstract][Full Text] [Related]
5. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
7. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y
Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688
[TBL] [Abstract][Full Text] [Related]
8. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
10. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
11. Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis.
Wang YY; Zhang T; Li SW; Qian TY; Fan X; Peng XX; Ma J; Wang L; Jiang T
AJNR Am J Neuroradiol; 2015 Jan; 36(1):70-6. PubMed ID: 25104286
[TBL] [Abstract][Full Text] [Related]
12. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
[TBL] [Abstract][Full Text] [Related]
14. Machine learning: a useful radiological adjunct in determination of a newly diagnosed glioma's grade and IDH status.
De Looze C; Beausang A; Cryan J; Loftus T; Buckley PG; Farrell M; Looby S; Reilly R; Brett F; Kearney H
J Neurooncol; 2018 Sep; 139(2):491-499. PubMed ID: 29770897
[TBL] [Abstract][Full Text] [Related]
15. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
16. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
20. Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
Mazurowski MA; Clark K; Czarnek NM; Shamsesfandabadi P; Peters KB; Saha A
J Neurooncol; 2017 May; 133(1):27-35. PubMed ID: 28470431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
